

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Xunfei Healthcare Technology Co., Ltd.**

**訊飛醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2506)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025**

At the annual general meeting (the “AGM”) of Xunfei Healthcare Technology Co., Ltd. (the “Company”) held on June 25, 2025, all the proposed resolutions as set out in the notice of AGM dated May 28, 2025 were taken by poll.

The poll results of the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the resolution on the 2024 work report of the board of directors (the “Board”) of the Company.	113,016,280 (99.9991%)	0 (0%)	1,000 (0.0009%)
2.	To consider and approve the resolution on the 2024 work report of the board of supervisors of the Company.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
3.	To consider and approve the resolution on the 2024 annual report of the Company.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
4.	To consider and approve the resolution on the application to banks for comprehensive credit lines.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
5.	To consider and approve the resolution on the 2024 financial settlement report of the Company.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
6.	To consider and approve the resolution on the 2024 profit distribution plan of the Company.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
7.	To consider and approve the resolution on the remuneration plan for directors and supervisors of the Company for 2025.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
8.	To consider and approve the resolution on the appointment of Deloitte Touche Tohmatsu as auditor of the Company for 2025, and to authorize the Board to fix its remuneration.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
9.	To consider and approve the resolution on the amendments to the Rules of Procedure of the General Meeting.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
10.	To consider and approve the resolution on the amendments to the Rules of Procedure of the Board of Directors.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
11.	To consider and approve the resolution on the abolition of the board of supervisors.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
12.	To consider and approve the resolution on the uncovered losses amounting to one-third of the total paid-up share capital.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)

Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
13.	To consider and approve the resolution on the guarantees for subsidiaries.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
14.	To consider and approve the resolution on the amendments to the Articles of Association.	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)
15.	To grant a general mandate to the directors of the Company to allot, issue and deal with (including sale or transfer of any treasury shares) additional Shares (details of this resolution were set out in the notice of AGM dated May 28, 2025).	112,973,533 (99.9613%)	42,750 (0.0378%)	1,000 (0.0009%)
16.	To grant a general mandate to the directors of the Company to repurchase H Shares (details of this resolution were set out in the notice of AGM dated May 28, 2025).	113,016,283 (99.9991%)	0 (0%)	1,000 (0.0009%)

*Notes:*

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 12, these resolutions were duly passed as ordinary resolutions.
- (b) As more than two-thirds of the votes were cast in favour of the resolutions numbered 13 to 16, these resolutions were duly passed as special resolutions.
- (c) As at the date of the AGM, the total number of shares of the Company in issue was 120,878,233 shares. The Company did not hold any treasury share or repurchase share pending cancellation as at the date of the AGM.
- (d) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 120,878,233 shares.
- (e) The Company's H share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (f) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

- (g) No shareholder was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (h) None of the shareholders of the Company have stated their intention in the Company's circular dated May 28, 2025 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (i) All directors of the board of directors of the Company attended the AGM either in person or through video or teleconference.
- (j) As resolution number 11 was duly passed at the AGM, the Board of Supervisors was abolished by the Company after the AGM, and each Supervisors resigned after the AGM. Each Supervisor confirmed that they did not have any disagreement with the Board during their tenure of office and there is no other matter in relation to their resignations that need to be brought to the attention of the Stock Exchange and the Shareholders. The Company would like to express its sincere gratitude and respect for the contributions made by the Supervisors to the Company during their tenure of office.

By order of the Board  
**Xunfei Healthcare Technology Co., Ltd.**  
**Dr. Tao Xiaodong**  
*Executive Director*

Hong Kong, June 25, 2025

*As at the date this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.*